頁籤選單縮合
題名 | 促胰泌降血糖藥與心血管疾病=Relationships between Insulin Secretagogues Drugs and Cardiovascular Diseases |
---|---|
作者 | 楊富喻; 童玟津; 陳鴻儀; Yang, Fu-yu; Tung, Wen-jin; Chen, Hung-yi; |
期刊 | 藥學雜誌 |
出版日期 | 20170900 |
卷期 | 33:3=132 2017.09[民106.09] |
頁次 | 頁54-59 |
分類號 | 418.271 |
語文 | chi |
關鍵詞 | 促胰泌降血糖藥; 磺胺尿素藥; 缺血預適應; Insulin secretagogues; Sulfonylureas; Ischemic preconditioning; |
中文摘要 | 低血糖反應是臨床上使用降血糖藥品最常見的不良反應,也是產生心血管疾病的 潛在危險因子之一,經常造成嚴重的神經學症狀,甚至導致死亡,耗費龐大的社會成 本。糖尿病是最常導致心血管疾病的病因之一,兩者互為共病症,文獻指出降血糖藥 品所致的低血糖反應是病人產生心血管疾病的主要原因。本文將朝此方向探討口服促 胰島素分泌 (簡稱促胰泌) 降血糖藥在糖尿病病人產生心血管疾病的影響。 許多研究顯示降血糖藥品能減少心血管事件的發生,我們回顧文獻卻發現磺胺尿 素類降血糖藥會增加心血管疾病影響,而格列奈類降血糖藥於統計學上沒有顯著差 異;使用磺胺尿素類藥品的病人罹患心血管疾病的風險相較使用其他口服降血糖藥品 為高,可能與藥品的缺血預適應 (ischemic preconditioning, IPC)、藥品造成的低血糖或 與病人的疾病嚴重度有關。 |
英文摘要 | Hypoglycemia is the most common side effect of antihyperglycemic drugs, it is also one of the potential risk factors for cardiovascular diseases (CVDs). This adverse effect often causes severe neurological symptoms and even death that it result in enormous social medical expenditures. Diabetes mellitus (DM) is one of the major risk factors for cardiovascular diseases, there are a lot of literatures show that antihyperglycemic drugs induced-hypoglycemia is the most reason for cause of CVDs in DM patients. Therefore, our purpose is to evaluate the relationships of insulin secretagogues (sulfonylureas and glinides) and CVDs in the DM patients. Although many evidences had suggested that antihyperglycemic drugs can reduce CVDs, our review show that the uses of sulfonylurea and the occurrence of CVDs have different results. Sulfonylureas were associated with risks of increasing CVDs compared with other antihyperglycemic drugs, whereas there is no significant difference in glinides. As mentioned above, those maybe resulted from many factors, including blocking ischemic preconditioning effect and hypoglycemia which were caused by drugs misuse and disease severity in DM patients. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。